On 8 February 2019 Health Canada released its "Overview of the format and content for post-market drug benefit-risk assessment in Canada – guidance document". The objective of the guidance document is to assist market authorisation holders in developing a post-market benefit-risk assessment for a marketed drug when requested.

The purpose of a benefit-risk assessment is to determine whether sufficient evidence exists to demonstrate that the benefits of a product continue to outweigh the risks. A benefit-risk assessment may, for example, be requested voluntarily or under the authority of Section 21.31 of the Food and Drugs Act and Section C.01.052 of the Food and Drug Regulations, which were enacted by the Protecting Canadians from Unsafe Drugs Act (Vanessa's Law) (for further details please see "Update on Vanessa's Law").

For further information on this topic please contact Katie Lee at Smart & Biggar/Fetherstonhaugh by telephone (+1 416 593 5514) or email ([email protected]). The Smart & Biggar/Fetherstonhaugh website can be accessed at www.smart-biggar.ca.